Kyodo Pharmaceutical disclosed its semi-annual report. In the first half of 2026, the company achieved operating income of 346 million yuan, an increase of 14.51% over the previous year; net profit attributable to shareholders of listed companies was a loss of 32.8413 million yuan, a loss of 11.1525 million yuan for the same period last year, an increase in year-on-year losses.

Kyodo Pharmaceutical disclosed its semi-annual report. In the first half of 2026, the company achieved operating income of 346 million yuan, an increase of 14.51% over the previous year; net profit attributable to shareholders of listed companies was a loss of 32.8413 million yuan, a loss of 11.1525 million yuan for the same period last year, an increase in year-on-year losses.